You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.
GeneCapture's platform would allow medical providers of all skill levels to quickly treat bacterial infections with the appropriate antibiotics in remote environments
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
The approach, which is developed for both Illumina and nanopore sequencing, had high sensitivity and specificity for identifying bacteria and fungi.
BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.
The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
With plasmid and chromosomal sequence data, European investigators identified three main routes for carbapenem antibiotic resistance spread in Klebsiella pneumoniae.
The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.